Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. Inactivated, attenuated, toxoid, subunit, conjugate, heterotypic, experimental, and valence are the types of vaccines.
U.S. vaccines market is estimated to account for US$ 19,355.2 Mn in terms of value in 2020 and is estimated to account for US$ 27,947.4 Mn by the end of 2027.
U.S. Vaccines Market: Drivers
Emergence of Covid-19 is expected to propel growth of the U.S. vaccines market over the forecast period. For instance, in the U.S. from January 20, 2020 to 6:01 pm CEST, 6 July 2020, there have been 2,833,552 confirmed cases of COVID-19 with 129,408 deaths, as reported to the World Health Organization.
Moreover, R&D initiatives for new vaccines is also expected to aid in growth of the market. For instance, in March 2020, IQVIA and Quest Diagnostics, through its joint venture Q2 Solutions, collaborated with the University of Texas Medical Branch to develop a novel assay for COVID-19 tests for rapid development of a Coronavirus vaccine.
Human vaccine held dominant position in the U.S. vaccines market in 2019, accounting for 81.7% share in terms of value, followed by animal vaccine respectively.
Figure 1. U.S. Vaccines Market Share (%), by Value, by Vaccine Type, 2019
U.S. Vaccines Market: Restraints
High cost of refrigeration of vaccines is expected to hinder growth of the market. For vaccines, refrigeration is mandatory to prevent alteration of their chemical structure mainly due to contact with water and humidity resulting in ineffective medications. Maintaining this cold chain from production until they are used in treatment is a costly process accounting for about 80% of the price of vaccinations.
Moreover, short functional shelf life of certain vaccines is also expected to limit the market growth.
U.S. Vaccines Market Report Coverage
||Market Size in 2019:
||US$ 18,367.0 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 27,947.4 Mn
- By Product Type:
- Human Vaccine: Pediatric Vaccines, Adult & Adolescent Vaccines, Other Human Vaccines.
- Animal Vaccine: Livestock Vaccines, Companion Animal Vaccines, Other Animal Vaccines.
- By End User: Hospitals, Clinics, Vaccination Centers.
Sanofi Pasteur, GlaxoSmithKline Plc, Merck & Company Incorporated, Pfizer Incorporated, AstraZeneca plc, and Boehringer Ingelheim
- High prevalence of infectious diseases
- Product launches
|Restraints & Challenges:
- Short functional shelf life of certain vaccines
- High costs
U.S. Vaccines Market: Opportunities
Building registry platform and database regarding COVID-19 is expected to offer lucrative growth opportunities for players in the U.S. vaccines market. For instance, in April 2020, Clara Health, a software startup, collaborated with Lyft, Inc., a ridesharing company, and VSC, a public relations agency, to build the registry platform and database to connect COVID-positive and -negative individuals with clinical trials for diagnostics, treatment and vaccine discovery.
Moreover, initiatives to promote R&D in poultry is also expected to aid in growth of the market. For instance, in May 2020, The U.S. Poultry Foundation awarded a US$ 7,000 grant to the University of North Georgia to recruit students into the poultry science program.
U.S. vaccines market was valued at US$ 18,367.0 Mn in 2019 and is forecast to reach a value of US$ 27,947.4 Mn by 2027 at a CAGR of 5.4% between 2020 and 2027.
Figure 2. U.S. Vaccines Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
Major players in the market are focused on adopting partnership and collaboration strategies to expand their product portfolio. For instance, in April 2020, Sanofi Pasteur collaborated with GSK to develop an adjuvanted vaccine for COVID-19.
Stringent regulations that promote vaccination are boosting the market growth. For instance, in January 2020, the Government of New Jersey, U.S., mandated college students to be vaccinated against bacterial meningitis as a condition for attending an institution.
The Center for Biologics Evaluation and Research (CBER) is the central regulatory agency responsible for ensuring purity, safety and efficacy of vaccines in the U.S.
U.S. Vaccines Market: Competitive Landscape
Major players operating in the U.S. vaccines market include, Sanofi Pasteur, GlaxoSmithKline Plc, Merck & Company Incorporated, Pfizer Incorporated, AstraZeneca plc, and Boehringer Ingelheim.
U.S. Vaccines Market: Key Developments
Major players in the market are focused on approval and launch of new vaccines to expand their product portfolio. For instance, in January 2020, Boehringer Ingelheim's U.S. Animal Health Business launched a vaccine, VAXXITEK HVT+IBD+ND that offers protection against Marek's Disease, Infectious Bursal Disease (classic and variant types) and Newcastle Disease.
Similarly, in December 2019, NewLink Genetics Corporation received the U.S. FDA approval for ERVEBO or Zaire Ebola virus vaccine V920.